Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx

[cafead]

via For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief medication Journavx, which was approved to much fanfare by the FDA two weeks ago.

article source